RT Journal Article
SR Electronic
T1 Non-pharmaceutical interventions to reduce influenza transmission in households: a systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.10.24313390
DO 10.1101/2024.09.10.24313390
A1 Wong, Jessica Y.
A1 Lim, Wey Wen
A1 Cheung, Justin K.
A1 Murphy, Caitriona
A1 Shiu, Eunice Y. C.
A1 Xiao, Jingyi
A1 Chen, Dongxuan
A1 Xie, Yanmin
A1 Li, Mingwei
A1 Xin, Hualei
A1 Szeto, Michelle
A1 Choi, Sammi
A1 Cowling, Benjamin J.
YR 2024
UL http://medrxiv.org/content/early/2024/09/10/2024.09.10.24313390.abstract
AB Background Influenza pandemic plans often recommend non-pharmaceutical interventions (NPIs) in household settings, including hand hygiene and face masks. We reviewed the evidence supporting the recommendations of these measures to prevent the spread of influenza in households.Methods We performed systematic reviews between 26 May and 30 August 2022 in Medline, PubMed, EMBASE, and CENTRAL to identify evidence for the effectiveness of selected measures recommended by representative national influenza pandemic plans. We prioritized evidence from randomized controlled trials. Fixed-effects models were used to estimate the overall effects. Systematic reviews were registered in the OSF registry (https://osf.io/8kyth).Results We selected 9 NPIs for evidence review. We identified 9 randomized-controlled trials related to hand hygiene and face masks in household settings. 2 studies reported that measures could delay the introduction of influenza virus infections into households. However, we did not identify evidence from randomized controlled trials that indicated a substantial effect of hand hygiene and face masks in preventing the spread of pandemic influenza within households.Conclusion Limited evidence indicated that within-household measures may likely be effective only when implemented before or as soon as possible after symptom onset in an infected case. Improving the evidence base for NPIs in households and elsewhere is a continuing priority.Funding World Health Organization and the Strategic Topic Grants SchemeCompeting Interest StatementB.J.C. has consulted for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. All other authors report no potential conflicts of interest.Funding StatementThis project was supported by a grant from the World Health Organization and the Strategic Topic Grants Scheme (Project No. STG4/M-701/23-N) of the Research Grants Council of the Hong Kong Special Administrative Region, China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In our systematic review and meta-analysis we only used data from published articlesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript